[Federal Register Volume 65, Number 129 (Wednesday, July 5, 2000)]
[Notices]
[Page 41476]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 00-16811]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration


Joint Meeting of the Transmissible Spongiform Encephalopathies 
Advisory Committee and the Vaccines and Related Biological Products 
Advisory Committee; Notice of Meeting

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

    This notice announces a forthcoming joint meeting of two public 
advisory committees of the Food and Drug Administration (FDA). At least 
one portion of the joint meeting will be closed to the public.
    Names of Committees: Transmissible Spongiform Encephalopathies 
Advisory Committee and the Vaccines and Related Biological Products 
Advisory Committee.
    General Function of the Committees: To provide advice and 
recommendations to the agency on FDA's regulatory issues.
    Date and Time: The meeting will be held on July 27, 2000, 8 a.m. to 
4 p.m.
    Location: Holiday Inn, Versailles Ballrooms I and II, 8120 
Wisconsin Ave., Bethesda, MD.
    Contact Person: William Freas or Sheila D. Langford; Nancy Cherry 
or Denise H. Royster, Center for Biologics Evaluation and Research 
(HFM-71), Food and Drug Administration, 1401 Rockville Pike, Rockville, 
MD 20852; 301-827-0314, or FDA Advisory Committee Information Line, 1-
800-741-8138 (301-443-0572 in the Washington, DC area), codes 12392 and 
12391. Please call the Information Line for up-to-date information on 
this meeting.
    Agenda: On July 27, 2000, in joint session, the committees will 
discuss bovine spongiform encephalopathy issues related to the 
manufacture of vaccines, specifically the use of European fetal calf 
serum in cell banks and viral seeds, and the use of European beef 
skeletal muscle and other tissues in manufacturing vaccines.
    Procedure: On July 27, 2000, from 9 a.m. to 4 p.m., the meeting is 
open to the public. Interested persons may present data, information, 
or views, orally or in writing, on issues pending before the committee. 
Written submissions may be made to the contact person by July 13, 2000. 
Oral presentations from the public will be scheduled between 
approximately 1 p.m. and 2 p.m. Time allotted for each presentation may 
be limited. Those desiring to make formal oral presentations should 
notify the contact person before July 17, 2000, and submit a brief 
statement of the general nature of the evidence or arguments they wish 
to present, the names and addresses of proposed participants, and an 
indication of the approximate time requested to make their 
presentations.
    Closed Committee Deliberations: On July 27, 2000, from 8 a.m. to 9 
a.m., the meeting will be closed to permit discussion and review of 
trade secret and/or confidential information (5 U.S.C. 552b(c)(4)).
    Notice of this meeting is given under the Federal Advisory 
Committee Act (5 U.S.C. app. 2).

    Dated: June 23, 2000.
Linda A. Suydam,
Senior Associate Commissioner.
[FR Doc. 00-16811 Filed 7-3-00; 8:45 am]
BILLING CODE 4160-01-F